GSC
ATOS icon

Ground Swell Capital’s Atossa Therapeutics ATOS Stock Holding History

Ground Swell Capital’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,333
Closed -$16.6K – 144
2025
Q2 		$16.6K Buy
+1,333
New +$15.9K 0.03% 107
2024
Q3 		– Sell
-964
Closed -$17.2K – 167
2024
Q2 		$17.2K Buy
+964
New +$21.3K 0.01% 137

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ground Swell Capital's ATOS Position: Q3 2025 in Review

Ground Swell Capital sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 1,333 shares — an estimated $16.6K sold.

Ground Swell Capital first reported a position in ATOS in Q2 2024 and held it in 2 quarters. The position peaked at $17.2K in Q2 2024. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Ground Swell Capital reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ground Swell Capital sold 1,333 Atossa Therapeutics shares in Q3 2025, an estimated $16.6K.
  • Ground Swell Capital first reported a position in Atossa Therapeutics in Q2 2024 and held it in 2 quarters.
  • Ground Swell Capital's Atossa Therapeutics position peaked at $17.2K in Q2 2024.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.